ArriVent Biopharma

Historical price data

Founded in 2021, ArriVent Biopharma identifies and in-licenses promising drug candidates from global innovation hubs, particularly China, to develop them for worldwide markets. The company's mission is to ensure differentiated medicines for difficult-to-treat cancers reach global patient populations. Led by a team with a proven track record in drug development and approvals, ArriVent's strategy leverages deep oncology expertise and regulatory experience to maximize the potential of its pipeline.

ArriVent's core platform is its strategic operating model: identifying and in-licensing promising late-preclinical or clinical-stage oncology assets from global innovation hubs (especially China) and leveraging deep development and regulatory expertise to accelerate their global development and commercialization.

5 drugs in pipeline, 3 in Phase 3

Total raised: $945M

Firmonertinib faces competition from other EGFR inhibitors like mobocertinib and amivantamab for Exon 20 insertions, and osimertinib for classical mutations. Its key differentiators are broad activity across mutation types and high brain penetration. In the ADC space, it will compete with major players like AstraZeneca and Merck, relying on novel constructs from its partners for differentiation.